Vitrafy Life Sciences Ltd (VFY)

Currency in AUD
1.73
0.00(0.00%)
Delayed Data·
VFY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.731.73
52 wk Range
1.081.95
Key Statistics
Bid/Ask
1.70 / 1.76
Prev. Close
1.73
Open
1.73
Day's Range
1.73-1.73
52 wk Range
1.08-1.95
Volume
3.34K
Average Volume (3m)
31.22K
1-Year Change
21.831%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VFY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.37
Upside
+37.13%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Vitrafy Life Sciences Ltd Company Profile

Vitrafy Life Sciences Limited engages in the research, development, and commercialization of cryopreservation solutions in Australia. The company offers smart devices, such as smart cryopreservation, smart thawing, and smart packaging devices. It also provides a software platform, which controls, trace, tracks, and monitors quality of cryopreserved biomaterials under the LifeChain brand. The company’s cryopreservation technology is used various applications, such as blood platelets, cell and gene therapies, and aquaculture and bovine breeding programs. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.

Vitrafy Life Sciences Ltd Earnings Call Summary for Q2/2026

  • Vitrafy Life Sciences maintains strong cash position of AUD 22-23 million, providing financial stability through 2027 despite a 2.94% stock drop in Q2 2026.
  • Company targets U.S. market expansion with Guardian cryopreservation devices, establishing new office and manufacturing capabilities while pursuing medical device certification.
  • Strategic partnership with IMV expected to generate monthly revenue of AUD 480,000, strengthening Vitrafy's position in the animal reproduction sector.
  • CEO Brent Owens highlighted 'really strong position' at year-end, while CFO Simon Martin emphasized focus on reducing manufacturing costs to achieve high gross margins.
  • Guidance includes plans for medical device registration in first half of next fiscal year, with future expansion targeted for Europe, UK, and Asia markets.
Last Updated: 02/03/2026, 05:52 PM
Read Full Transcript

Compare VFY to Peers and Sector

Metrics to compare
VFY
Peers
Sector
Relationship
P/E Ratio
−7.8x−2.0x−0.5x
PEG Ratio
−0.09−0.020.00
Price/Book
5.1x1.7x2.6x
Price / LTM Sales
47.1x4.9x3.3x
Upside (Analyst Target)
37.4%228.2%44.8%
Fair Value Upside
Unlock9.7%5.0%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.37
(+37.13% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Feb 03, 2026
EPS / Forecast
-0.11 / --
Revenue / Forecast
1.98M / --
EPS Revisions
Last 90 days

VFY Income Statement

People Also Watch

3.960
IMD
+1.02%
0.046
HGO
0.00%
98.34
HUB
-0.11%
0.510
AIS
-1.92%

FAQ

What Is the Vitrafy Life Sciences (VFY) Stock Price Today?

The Vitrafy Life Sciences stock price today is 1.73

What Stock Exchange Does Vitrafy Life Sciences Trade On?

Vitrafy Life Sciences is listed and trades on the Sydney Stock Exchange.

What Is the Stock Symbol for Vitrafy Life Sciences?

The stock symbol for Vitrafy Life Sciences is "VFY."

What Is the Vitrafy Life Sciences Market Cap?

As of today, Vitrafy Life Sciences market cap is 110.46M.

What Is Vitrafy Life Sciences's Earnings Per Share (TTM)?

The Vitrafy Life Sciences EPS (TTM) is -0.22.

From a Technical Analysis Perspective, Is VFY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Vitrafy Life Sciences Stock Split?

Vitrafy Life Sciences has split 0 times.

What is the current trading status of Vitrafy Life Sciences (VFY)?

As of Feb 20, 2026, Vitrafy Life Sciences (VFY) is trading at a price of 1.73, with a previous close of 1.73. The stock has fluctuated within a day range of 1.73 to 1.73, while its 52-week range spans from 1.08 to 1.95.

What Is Vitrafy Life Sciences (VFY) Price Target According to Analysts?

The average 12-month price target for Vitrafy Life Sciences is AUD2.37, with a high estimate of AUD2.50637936 and a low estimate of AUD2.23844627. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +37.13% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.